FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079138093> ?p ?o ?g. }

• W2079138093 endingPage "S122" @default.
• W2079138093 startingPage "S122" @default.
• W2079138093 abstract "45 patients (pts), 26 male & 19 female with gastric AC, with non-resectable adenocarcinoma were treated with E (50 mg/m2) and C (60 mg/m2) given every 3 weeks, with a continuous ambulatory infusion of F (200 mg/m2 per day). A cohort of 19 pts presenting from April 1993 to Sept 1994 were added to 26 previously reported cases. ECOG score 0-1, median age 61 (29-81), 258 cycles were given (1–12, median 6). All pts had a degree of alopecia no greater than Grade III. A single case of grade IV toxicity was seen (diarrhea). Grade III toxicity was seen as follows: vomiting 2 pts, diarrhea 2 pts, stomatitis 2 pts, infection 5 pts. Nine pts had mild foot & mouth syndrome. Five pts were not evaluable for response (3 early deaths and 2 stopped early due to toxicity). Of 40 evaluable pts, reassessed at 9 weeks, 57% responded- 2 (5%) CR, 21 (52%) PR, 13 stable disease & 4 progressed. Median survival was 9 months (1.4- 41+). We conclude that ECF has a high response rate in non-resectable gastric AC. Response rates in this cohort were similar to our previous report. A randomised phase III trial of ECF versus FAMTX, is open for accrual to assess the true value of this innovative regimen. 45 patients (pts), 26 male & 19 female with gastric AC, with non-resectable adenocarcinoma were treated with E (50 mg/m2) and C (60 mg/m2) given every 3 weeks, with a continuous ambulatory infusion of F (200 mg/m2 per day). A cohort of 19 pts presenting from April 1993 to Sept 1994 were added to 26 previously reported cases. ECOG score 0-1, median age 61 (29-81), 258 cycles were given (1–12, median 6). All pts had a degree of alopecia no greater than Grade III. A single case of grade IV toxicity was seen (diarrhea). Grade III toxicity was seen as follows: vomiting 2 pts, diarrhea 2 pts, stomatitis 2 pts, infection 5 pts. Nine pts had mild foot & mouth syndrome. Five pts were not evaluable for response (3 early deaths and 2 stopped early due to toxicity). Of 40 evaluable pts, reassessed at 9 weeks, 57% responded- 2 (5%) CR, 21 (52%) PR, 13 stable disease & 4 progressed. Median survival was 9 months (1.4- 41+). We conclude that ECF has a high response rate in non-resectable gastric AC. Response rates in this cohort were similar to our previous report. A randomised phase III trial of ECF versus FAMTX, is open for accrual to assess the true value of this innovative regimen." @default.
• W2079138093 created "2016-06-24" @default.
• W2079138093 creator A5002008554 @default.
• W2079138093 creator A5011528245 @default.
• W2079138093 creator A5012884004 @default.
• W2079138093 creator A5016743302 @default.
• W2079138093 creator A5032873478 @default.
• W2079138093 creator A5035934475 @default.
• W2079138093 creator A5048528745 @default.
• W2079138093 creator A5051878827 @default.
• W2079138093 creator A5052620856 @default.
• W2079138093 creator A5057831510 @default.
• W2079138093 creator A5065717193 @default.
• W2079138093 creator A5070581787 @default.
• W2079138093 creator A5079189753 @default.
• W2079138093 date "1995-11-01" @default.
• W2079138093 modified "2023-10-14" @default.
• W2079138093 title "575 Epirubicin (E), cisplatin (C) and continuous infusional 5-fluorouracil (F) (ECF) active combination chemotherapy for non-resectable gastric adenocarcinoma (AC)" @default.
• W2079138093 doi "https://doi.org/10.1016/0959-8049(95)95829-u" @default.
• W2079138093 hasPublicationYear "1995" @default.
• W2079138093 type Work @default.
• W2079138093 sameAs 2079138093 @default.
• W2079138093 citedByCount "0" @default.
• W2079138093 crossrefType "journal-article" @default.
• W2079138093 hasAuthorship W2079138093A5002008554 @default.
• W2079138093 hasAuthorship W2079138093A5011528245 @default.
• W2079138093 hasAuthorship W2079138093A5012884004 @default.
• W2079138093 hasAuthorship W2079138093A5016743302 @default.
• W2079138093 hasAuthorship W2079138093A5032873478 @default.
• W2079138093 hasAuthorship W2079138093A5035934475 @default.
• W2079138093 hasAuthorship W2079138093A5048528745 @default.
• W2079138093 hasAuthorship W2079138093A5051878827 @default.
• W2079138093 hasAuthorship W2079138093A5052620856 @default.
• W2079138093 hasAuthorship W2079138093A5057831510 @default.
• W2079138093 hasAuthorship W2079138093A5065717193 @default.
• W2079138093 hasAuthorship W2079138093A5070581787 @default.
• W2079138093 hasAuthorship W2079138093A5079189753 @default.
• W2079138093 hasConcept C126322002 @default.
• W2079138093 hasConcept C141071460 @default.
• W2079138093 hasConcept C2776694085 @default.
• W2079138093 hasConcept C2776755627 @default.
• W2079138093 hasConcept C2778496288 @default.
• W2079138093 hasConcept C2779051857 @default.
• W2079138093 hasConcept C2780456651 @default.
• W2079138093 hasConcept C2780835546 @default.
• W2079138093 hasConcept C2780852908 @default.
• W2079138093 hasConcept C2781413609 @default.
• W2079138093 hasConcept C29730261 @default.
• W2079138093 hasConcept C35785553 @default.
• W2079138093 hasConcept C71924100 @default.
• W2079138093 hasConcept C72563966 @default.
• W2079138093 hasConcept C90924648 @default.
• W2079138093 hasConceptScore W2079138093C126322002 @default.
• W2079138093 hasConceptScore W2079138093C141071460 @default.
• W2079138093 hasConceptScore W2079138093C2776694085 @default.
• W2079138093 hasConceptScore W2079138093C2776755627 @default.
• W2079138093 hasConceptScore W2079138093C2778496288 @default.
• W2079138093 hasConceptScore W2079138093C2779051857 @default.
• W2079138093 hasConceptScore W2079138093C2780456651 @default.
• W2079138093 hasConceptScore W2079138093C2780835546 @default.
• W2079138093 hasConceptScore W2079138093C2780852908 @default.
• W2079138093 hasConceptScore W2079138093C2781413609 @default.
• W2079138093 hasConceptScore W2079138093C29730261 @default.
• W2079138093 hasConceptScore W2079138093C35785553 @default.
• W2079138093 hasConceptScore W2079138093C71924100 @default.
• W2079138093 hasConceptScore W2079138093C72563966 @default.
• W2079138093 hasConceptScore W2079138093C90924648 @default.
• W2079138093 hasLocation W20791380931 @default.
• W2079138093 hasOpenAccess W2079138093 @default.
• W2079138093 hasPrimaryLocation W20791380931 @default.
• W2079138093 hasRelatedWork W1980701009 @default.
• W2079138093 hasRelatedWork W2051535219 @default.
• W2079138093 hasRelatedWork W2316688895 @default.
• W2079138093 hasRelatedWork W2345926325 @default.
• W2079138093 hasRelatedWork W2370897712 @default.
• W2079138093 hasRelatedWork W2382265168 @default.
• W2079138093 hasRelatedWork W2410470690 @default.
• W2079138093 hasRelatedWork W2411075028 @default.
• W2079138093 hasRelatedWork W2465078823 @default.
• W2079138093 hasRelatedWork W2947501674 @default.
• W2079138093 hasVolume "31" @default.
• W2079138093 isParatext "false" @default.
• W2079138093 isRetracted "false" @default.
• W2079138093 magId "2079138093" @default.
• W2079138093 workType "article" @default.